Dr. Clay Siegall’s recent interview with Inspirery reveals some excellent insights into his character. Clay Siegall is the CEO and founder of Seattle Genetics. His bitotech firm is operates out of Seattle. The firm specializes in developing therapy drugs that target specific disease types. His research and results look promising. There has been a substantial improvement in the mortality rate of patients who use his drugs.
His educational background is in zoology, and he holds a B.S. degree. He went on to receive his Ph.D in Genetics from George Washington University. The targeted therapy field of medicine is still relatively new. However, his firm is a disrupter in the industry in having developed the first antibody conjugate that was FDA-approved. Siegall also takes credit for having developed more than 20 drugs along with strategic partnerships to manufacture his drugs. These partnerships include Bayer, Pfizer, and Genetech to name several.
His company has also experienced robust growth since its inception. It is now a major player in the cancer research space, and has come a long way from its tiny startup days. As such, Seattle Genetics positions itself to continue expanding its list of drugs within a vibrant pipeline of products. The applications for, already existing, his drugs offer unlimited opportunities for potential applications. His company will continue to be a major contender well into the 21st century.
Siegall’s drive to create targeted therapy drugs comes from his belief that the old ways of treating cancer with processes like chemotherapy will become a relic of the past. Even though targeted therapies are in their initial stage, it continually becomes clearer they will become the way of the near future. Targeted drugs will likely replace harsh, older, therapies.
The world always moves forward. Thus, one can expect new thoughts, ideas, methods, and products to continually materialize. Clay Siegall is a true innovator in his field, and the world will be a better place for his energy and creativity.
Cancer is one of the most deadly diseases in the world and is responsible for taking millions of lives globally each year. The area of cancer research, even though has seen positive signs of development in recent years, is yet to find a cure for this deadly epidemical disease. The researchers, scientists, oncologists, and physicians from around the world gathered at the Fortune Brainstorm Health Conference that was recently held in San Diego, which was also attended by Eric Lefkofsky, as a co-founder of Tempus.
At the conference, Mr Lefkofsky mentioned that thousands of lives could be saved each year if there is sufficient amount of accurate data is made available to the physicians to provide cancer treatment. Tempus, one of the many start-ups of Eric Lefkofsky, is a technology firm dedicated to collecting molecular, clinical, therapeutic, and outcome response data from many different sources to provide it in an integrated manner to the researchers and physicians. With the help of such data available quickly and in a free-flowing manner, it would become much easier for the researchers and doctors to understand the loopholes in their research and treatment respectively. It would help the concerned experts to make necessary changes and provide better cancer therapies that are result driven and productive.
Combining the power of technology with cancer research can help with accelerating the progress in the field of cancer research is what Eric Lefkofsky truly believes. Even though Eric belongs to an entirely different genre of business, and is popularly known for his company, GrouponInc, which is an e-commerce platform for merchants to offer lucrative deals to consumers, he delved into the field of cancer research after his wife was diagnosed with Breast cancer.
The idea behind Tempus is to help the field of cancer research to get a clean version of clinical and therapeutic data for verification and validation. It would save time, effort, and potentially lives of millions of people when implemented on a global scale, is what Eric Lefkofsky believes. Eric Lefkofsky is also the founder and co-founder of many other companies, including Echo Global Logistics, Uptake Technologies, Lightbank, and Mediaocean.
Eric Lefofsky’s wife was diagnosed with cancer after just a short time of him being retired. His wife is fine now, but Eric has always wanted to do something to help people. The cancer diagnosis that his wife received was just what he needed to help get him in gear to do something to help other people. He wants to make sure that things are great for everyone and that all families who are affected by a cancer diagnosis are able to get what they need from the different resources that he is able to provide. He has done this through his own company instead of trying to rely on the help of a charity that he doesn’t know who is running it. Mr Lefofsky is the best person for the job because he knows how much he wants to help people and make their lives better so that they can do more with what they have.
The company that Eric Lefofsky started for people who were affected by cancer is Tempus. This is a company that works to help people get the things that they need but it also helps people with a cure for cancer. Obviously, the geneticist who works for the company with Eric has not found the cure for cancer yet but he is working diligently to make sure that he is doing what he can to help find the cure for cancer. He wants to show people that there is more to offer the people who have cancer and he wants to cure it. Click here to know more.
Tempus is not the only company that Eric Lefofsky has come up with the idea for. He worked with many different people and came up with the idea for Groupon. He just wanted to start the company to show people what they were able to do and the deals that they were able to get but it grew to something that was so much bigger and better than when it first started. Eric Lefkofsky saw a huge success with Groupon and was actually able to retire much earlier than what he ever thought possible.